Salivary secretion, mucin concentrations and candida carriage in HIV-infected patients

Oral Diseases

Volumn 15, Issue 3, 2009, Pages 229-234

  Jainkittivong, A ^a   Lin, A L ^b   Johnson, D A ^b   Langlais, R P ^b   Yeh, C K ^b,c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Candida; HIV; Mucin; Saliva

Indexed keywords

MUCIN; SALIVA PROTEIN;

ADULT; ARTICLE; CANDIDA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SALIVA LEVEL; SALIVATION; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDA; CANDIDIASIS; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MUCINS; SALIVA; SALIVATION; SECRETORY RATE; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND; XEROSTOMIA;

EID: 62749174593     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2009.01514.x     Document Type: Article

References (50)

1. Almstahl A, Wikstraom M, Groenink J (2001). Lactoferrin, amylase and mucin MUC5B and their relation to the oral microflora in hyposalivation of different origins. Oral Microbiol Immunol 16 : 345 352.
2. Arneberg P (1971). Quantitative determination of protein in saliva. A comparison of analytical methods. Scand J Dent Res 79 : 60 64.
3. Atkinson JC, Yeh CK, Bermudez D et al (1989). Longitudinal evaluation of major salivary gland function in HIV-1 infected patients. J Oral Pathol Med 18 : 469 470.
4. Atkinson JC, Yeh C, Oppenheim FG et al (1990). Elevation of salivary antimicrobial proteins following HIV-1 infection. J Acquir Immune Defic Syndr 3 : 41 48.
5. Baughan LW, Robertello FJ, Sarrett DC et al (2000). Salivary mucins as related to oral Streptococcus mutans in elderly people. Oral Microbiol Immunol 15 : 10 14.
6. Bergey EJ, Cho MI, Hammarskjild ML et al (1993). Aggregation of human immunodeficiency virus type 1 by human salivary secretions. Crit Rev Oral Biol Med 4 : 467 474.
7. Campisi G, Pizzo G, Millici ME et al (2002). Candida carriage in the oral cavity of human immunodeficiency virus-infected subjects. Oral Surg Oral Med Oral Pathol 93 : 281 286.
8. Cohen RE, Aguirre A, Neiders ME et al (1990). Immunochemistry of high molecular weight human salivary mucin. Arch Oral Biol 35 : 127 136.
9. Cohen RE, Aguirre A, Neiders ME et al (1991). Immunochemistry and immunogenicity of low molecular weight human salivary mucin. Arch Oral Biol 36 : 347 356.
10. Denny PC, Denny PA, Klauser DK et al (1991). Age-related changes in mucins from human whole saliva. J Dent Res 70 : 1320 1327.
11. Ellepola ANB, Samaranayake LP (2001). Inhalation and topical steroids, and oral candidosis: a mini review. Oral Dis 7 : 211 216.
12. Enwonwu CO, Meeks VI (1996). Oral candidiasis, HIV, and saliva glucocorticoids. Am J Pathol 148 : 1313 1318.
13. Fox PC, Wolff A, Yeh CK et al (1988). Saliva inhibits HIV-1 infectivity. J Am Dent Assoc 116 : 635 637.
14. Greenberg MS, Glick M, Nghiem L et al (1997). Relationship of cytomegalovirus to salivary gland dysfunction in HIV-infected patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83 : 334 339.
15. Greenspan D, Komaroff E, Redford M et al (2000). Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 25 : 44 50.
16. Habte HH, Mall AS, de Beer C et al (2006). The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of human immuno-deficiency virus type 1 in an inhibition assay. Virology J 3 : 99 110.
17. Hirsch HH, Kaufmann G, Sendi P et al (2004). Immune reconstitution in HIV-infected patients. Clin Infect Dis 38 : 1159 1166.
18. Jainkittivong A, Johnson DA, Yeh CK (1998). The relationship between salivary histatin levels and oral yeast carriage. Oral Microbiol Immunol 13 : 181 187.
19. Klein RS, Harris CA, Small CB et al (1984). Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 311 : 354 358.
20. Levine MJ, Herzberg MC, Levine MS et al (1978). Specificity of salivary-bacterial interactions: role of terminal sialic acid residues in the interaction of salivary glycoproteins with Streptococcus sanquis and Streptococcus mutans. Infect Immun 19 : 107 115.
21. Lin AL, Johnson DA, Patterson TF et al (2001). Salivary anticandidal activity and saliva composition in an HIV-infected cohort. Oral Microbiol Immunol 16 : 270 278.
22. Lin AL, Johnson DA, Stephan KT et al (2003). Alteration in salivary function in early HIV infection. J Dent Res 82 : 719 724.
23. Lin AL, Johnson DA, Sims CA et al (2006). Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 : 318 324.
24. Liu B, Offner GD, Nunes DP et al (1998). MUC4 is a major component of salivary mucin MG1 secreted by the human submandibular gland. Biochem Biophys Res Commun 250 : 757 761.
25. Mandel ID (1987). The functions of saliva. J Dent Res 66 : 623 627.
26. Mandel ID, Barr CE, Turgeon L (1992). Longitudinal study of parotid saliva in HIV-1 infection. J Oral Pathol Med 21 : 209 213.
27. Nagashunmugam T, Friedman HM, Davis C et al (1997). Human submandibular saliva specifically inhibits HIV type 1. AIDS Res Hum Retroviruses 13 : 371 376.
28. Navazesh M, Mulligan RA, Komaroff E et al (2000). The prevalence of xerostomia and salivary gland hypofunction in a cohort of HIV-positive and at-risk women. J Dent Res 79 : 1502 1507.
29. Navazesh M, Mulligan RA, Barron Y et al (2003). A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 : 693 698.
30. Navazesh M, Mulligan RA, Pogoda J et al (2005). The effect of HAART on salivary microbiota in the Women's Interagency HIV Study (WIHS). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 : 701 708.
31. Nielsen PA, Mandel U, Therkildsen MH et al (1996). Differential expression of human high-molecular-weight salivary mucin (MG1) and low-molecular-weight salivary mucin (MG2). J Dent Res 75 : 1820 1826.
32. Nielsen PA, Bennett EP, Wandall HH et al (1997). Identification of a major human high molecular weight salivary mucin (MG1) as tracheobronchial mucin MUC5B. Glycobiology 7 : 413 419.
33. Ogasawara A, Komaki N, Akai H et al (2007). Hyphal formation of Candida albicans is inhibited by salivary mucin. Biol Pharm Bull 30 : 284 286.
34. Ohmit SE, Sobel JD, Schuman P et al (2003). Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 188 : 118 127.
35. Patel M, Shackleton JT, Coogan MM (2006). Effect of antifungal treatment on the prevalence of yeasts in HIV-infected subjects. J Med Microbiol 55 : 1279 1284.
36. Pollock JJ, Santarpia RP 3rd., Heller HM et al (1992). Determination of salivary anticandidal activities in healthy adults and patients with AIDS: a pilot study. J Acquir Immune Defic Syndr 5 : 610 618.
37. Rayment SA, Liu B, Offner GD et al (2000). Immunoquantification of human salivary mucins MG1 and MG2 in stimulated whole saliva: factors influencing mucin levels. J Dent Res 79 : 1765 1772.
38. Reichart PA (2003). Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma. Med Microbiol Immunol 192 : 165 169.
39. Scannapieco FA (1994). Saliva-bacterium interaction in oral microbial ecology. Crit Rev Oral Biol Med 5 : 203 248.
40. Schneyer LH (1956). Source of resting total mixed saliva of man. J Appl Physiol 9 : 79 81.
41. Situ H, Wei G, Smith CJ et al (2003). Human salivary MUC7 mucin peptides: effect of size, charge and cysteine residues on antifungal activity. Biochem J 375 : 175 182.
42. Tabak LA (1990). Structure and function of human salivary mucins. Crit Rev Oral Biol Med 1 : 229 234.
43. Teanpaisan R, Nittayananta W (1998). Prevalence of Candida species in AIDS patients and HIV-free subjects in Thailand. J Oral Pathol Med 27 : 4 7.
44. Thornton DJ, Khan N, Mehrotra R et al (1999). Salivary mucin MG1 is compromised almost entirely of different glycosylated form of the MUC5B gene product. Glycobiology 9 : 293 302.
45. Troxler RF, Iontcheva I, Oppenheim FG et al (1997). Molecular characterization of a major high molecular weight mucin from human sublingual gland. Glycobiology 7 : 965 973.
46. Tsang CS, Samaranayake LP (2000). Oral yeasts and coliforms in HIV-infected individuals in Hong Kong. Mycoses 43 : 303 308.
47. Yang YL, Lo HJ, Hung CC et al (2006). Effect of prolonged HAART on oral colonization with Candida and candidiasis. BMC Infectious Diseases 6 : 8 11.
48. Yeh CK, Fox PC, Ship JA et al (1988). Oral defense mechanisms are impaired early in HIV-1 infected patients. J Acquir Immune Defic Syndr 1 : 361 366.
49. Yeh CK, Handelman B, Fox PC et al (1992). Further studies of salivary inhibition of HIV-1 infectivity. J Acquir Immune Defic Syndr 5 : 898 903.
50. Zalewska A, Zwierz K, Zolkowska K et al (2000). Structure and biosynthesis of human salivary mucins. Acta Biochim Pol 47 : 1067 1079.